MesoblastASX:MSB -9.38%46 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates ASX:MSB with a GF Score™ of 46/100. The stock has 4 warning signs investors should review. Among 707 Biotechnology companies, Mesoblast ranks worse than 141442.57% on this metric.
The historical rank and industry rank for Mesoblast's Days Payable or its related term are showing as below:
During the past 13 years, Mesoblast's highest Days Payable was 925.40. The lowest was 925.40. And the median was 925.40.
ASX:MSB's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.76 * Ranked among companies with meaningful Days Payable only.
Mesoblast's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
stayed the same
Mesoblast Days Payable Related Terms
Mesoblast Days Payable Historical Data
* Premium members only.
The historical data trend for Mesoblast's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:MSB vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Mesoblast's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mesoblast Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mesoblast's Days Payable distribution charts can be found below:
* The bar in red indicates where Mesoblast's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Mesoblast's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mesoblast (ASX:MSB) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mesoblast and its competitors. Over the past decade, Mesoblast's Days Payable has ranged from 925.40 to 925.40. According to the industry distribution chart, Mesoblast ranks #999999 out of 707 companies in the Biotechnology industry.
Is Mesoblast's Days Payable too high?
Mesoblast's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 925.40 to a high of 925.40. Based on the distribution chart, Mesoblast ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Mesoblast has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mesoblast ranks #999999 out of 707 companies for Days Payable. This places Mesoblast in the lower half of its industry. The industry median Days Payable is 113.76. Historically, Mesoblast's own Days Payable has ranged from 925.40 to 925.40 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mesoblast and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mesoblast's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current Days Payable of 0.00. The current Days Payable is 0.00. Mesoblast's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
46GF Score
Get the complete analysis for ASX:MSB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MSB has been successfully added to your 
